FindTrial
Sign In

Mid- to longterm outcome after severe COVID-19 associated respiratory failure with Extracorporeal Membrane Oxygenation (ECMO) therapy

Mid- to longterm outcome after severe COVID-19 associated respiratory failure with Extracorporeal Membrane Oxygenation (ECMO) therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00026752
Enrollment
30
Registered
2021-10-08
Start date
2021-10-06
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19-related severe hypoxemic respiratory failure

Interventions

Group 1: All patients suffering from COVID-19 who were treated with ECMO therapy at the Heart and Diabetes Center from 04/01/2020 to 04/30/2021. In these patients, the survey of health status and qual

Sponsors

Herz- u. Diabeteszentrum NRW, Klinik für Thorax- und Kardiovaskularchirurgie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Covid-19 patients treated with ECMO therapy at the HDZ NRW since the beginning of the pandemic until April 2021.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Health status and quality of life one year, two years, and five years after initiation of ECMO therapy. The surveys are conducted using standardized and established questionnaires in telephone or postal form.—

Countries

Germany

Contacts

Public ContactSabina Günther

Herz- u. Diabeteszentrum NRWKlinik für Thorax- u. Kardiovaskularchirurgie

saguenther@hdz-nrw.de05731-97-3130

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026